StreetAlpha.app
Home › Stocks › OCS

Oculis Holding AG (OCS)

Healthcare
$7.06
▼ −5.11%
LAST CLOSE · NOV 20

Oculis develops late stage drug candidates for eye and optic nerve diseases, based in Zug, Switzerland. It last closed at $7.06 on Nov 20, down 5.11% on the day.

AI Auto Pilots
Is OCS in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold OCS.

Key Stats

Last 12 months
Results
Net income
−CHF 99.0M
Free cash flow
−CHF 66.6M
Balance sheet
Cash & equivalents
CHF 81.3M
At Dec 31
Shareholder equity
CHF 196.1M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −CHF 18.6M−CHF 18.6MFY2021FY2022: −CHF 38.7M−CHF 38.7MFY2022FY2023: −CHF 88.8M−CHF 88.8MFY2023FY2024: −CHF 85.8M−CHF 85.8MFY2024FY2025: −CHF 99.0M−CHF 99.0MFY2025

From OCS's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Mar 4). Last 12 months adds up the four latest quarters. Figures are in CHF. Per share figures are left out because the US listing can represent a different number of shares.

Next report
—
No date on the calendar yet
Consensus EPS forecast
EPS and revenue estimates
Year-ago EPS
Same quarter last year
Options-implied move
Move priced in by options
Analyst consensus
Ratings from the last 90 days
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on OCS
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on OCS

Technical Analysis

OCS · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 8% below its 20 day and 18% below its 50 day average. It is 146% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 36), near oversold. The nearest support is the Pivot S1 at $6.88, and the nearest resistance the Pivot at $7.16.

Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityHigh, 7.9%/day
Key levels
$34.4852 week high+388.4%
$17.35200 day average+145.8%
$10.37100 day average+46.9%
$8.3350 day average+18.0%
$8.04Swing high (Nov 9)+13.9%
$7.6220 day average+7.9%
$7.34Pivot R1+4.0%
$7.16Pivot+1.4%
$7.06Last close
$6.88Pivot S1−2.5%
$6.7852 week low−4.0%
$6.78Swing low (Nov 5)−4.0%
Indicators
RSI (14)36.20Weak, oversold below 30Neutral
MACD-0.29Above its signal lineBullish
Stochastic28.9Middle of its rangeNeutral
ADX (14)21.1Weak trend
Williams %R-80.4Oversold below −80, overbought above −20Oversold
CCI (20)-124.8Oversold below −100, overbought above 100Oversold
Rate of change−5.7%Change over 10 sessionsBearish
ATR (14)$0.56Typical daily range, 7.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for OCS

What happened before

See how OCS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow OCS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How OCS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2023.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for OCSHow many large options trades hit OCS, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

OCS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲42 buying vs 26 selling
  • ▲Shares held by funds +7.9%
  • ▲Funds holding +9
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding6960+15.0%
In funds' top 1034−25.0%
Held by funds–––
New / increased19 / 2322 / 23−6.7%
Reduced / sold out16 / 109 / 18−3.7%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See OCS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether OCS is in one of them and how their past OCS trades turned out.

OCS in the AI portfolios
Loading…

OCS News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered OCS in an article yet. Here's the latest on the wider market.

OCS in the news

About Oculis Holding AG

Oculis is a biopharmaceutical company based in Zug, Switzerland, with operations in the U.S. and Iceland. It develops drug candidates for diseases of the eye and optic nerve. Its pipeline includes OCS-01, an eye drop being studied for diabetic macular edema, Licaminlimab, a topical treatment for dry eye disease, and Privosegtor, a neuroprotective candidate for optic neuritis and a related nerve condition. Its intended customers are patients and eye care doctors.

Headquarters
Zug, Switzerland